ArticleCell reports2022
Distinct gene expression by expanded clones of quiescent memory CD4
Open access · goldAbstract read
In one paragraph
Article in Cell reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
2.8field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Innate immune imprints shape HIV-1 reservoir cell persistence during long-term antiretroviral therapy.Nature immunology · 2026Article
- Article
- Transcription of HIV-1 is heterogenous among authentic latent CD4+ T cell clones.The Journal of experimental medicine · 2026Article
- Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence.Current HIV/AIDS reports · 2026Review
- Article
- Tools to Quantify and Characterize the Persistent Reservoir in People with HIV-1: Focus on Non-B Subtypes.Viruses · 2026Review
- BACH2 promotes seeding and establishment of long-lived HIV-1 reservoir in memory CD4Cell reports. Medicine · 2025Article
- Single cell technologies and the biology of HIV-infected CD4 T-cell reservoirs.Current opinion in HIV and AIDS · 2025Review
- Cystatin F-a key player in central nervous system disease.Journal of neuroinflammation · 2025Review
- Advancements in single-cell techniques for examining the HIV reservoir: pathways to a cure.mBio · 2025Review
- Tracking HIV persistence across T cell lineages during early ART-treated HIV-1-infection using a reservoir-marking humanized mouse model.Nature communications · 2025Article
- Blood and tissue HIV-1 reservoirs display plasticity and lack of compartmentalization in virally suppressed people.Nature communications · 2025Article
- Enhanced conversion of T cells into CAR T cells by modulation of the MAPK/ERK pathway.Cell reports. Medicine · 2025Article
- Phenotyping Viral Reservoirs to Reveal HIV-1 Hiding Places.Current HIV/AIDS reports · 2025Review
- Transcriptomic HIV-1 reservoir profiling reveals a role for mitochondrial functionality in HIV-1 latency.PLoS pathogens · 2025Article
- Double, double toil and trouble: transforming growth factor beta (TGF-β) in HIV infection.Frontiers in immunology · 2025Review
- Transcription of HIV-1 at sites of intact latent provirus integration.The Journal of experimental medicine · 2024Article
- Immune targeting of HIV-1 reservoir cells: a path to elimination strategies and cure.Nature reviews. Microbiology · 2024Review
- Transcription of HIV-1 at sites of intact latent provirus integration.bioRxiv : the preprint server for biology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Georg H J WeymarLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Yotam Bar-OnTechnion - Israel Institute of Technology, Haifa 320003, Israel.
Thiago Y OliveiraLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Christian GaeblerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Victor RamosLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Harald HartwegerLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Gaëlle BretonLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Marina CaskeyLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Lillian B CohnVaccine and Infectious Diseases Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.
Mila JankovicLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA.
Michel C NussenzweigLaboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA; Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA. Electronic address: nussen@rockefeller.edu.
Rockefeller University · USFred Hutch Cancer Center · USHoward Hughes Medical Institute · USTechnion – Israel Institute of Technology · IL
Funding
Support Component D/Vaccine Discovery, Concept to ClinicUM1AI100663 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI CRISPIN, MAX · 2012 to 2018
$131.5MStuctural basis of bNab activityP01AI100148 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI Pamela J Bjorkman · 2013 to 2026
$43.3MDeveloping, Demonstrating, and Disseminating Innovative Programs to Achieve Translational SuccessUL1TR001866 · NCATS · ROCKEFELLER UNIVERSITY · PI COLLER, BARRY, KRUEGER, JAMES G · 2016 to 2025
$40.6MREACH: Research Enterprise to Advance a Cure for HIVUM1AI164565 · NIAID · WEILL MEDICAL COLL OF CORNELL UNIV · PI Marina Caskey, R. Brad Jones · 2021 to 2026
$32.9MPatient and Population Health Outcomes Research SWGP30AI124414 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE, INC · PI HARRIS GOLDSTEIN · 2017 to 2026
$28.3MDelaney AIDS Research Enterprise to Cure HIVUM1AI126611 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DEEKS, STEVEN GRANT, PICKER, LOUIS J. · 2016 to 2020
$27.9MFirst-in-human study of two anti-SARS CoV-2 antibodies in health volunteersUM1AI126620 · NIAID · WISTAR INSTITUTE · PI MONTANER, LUIS J, RILEY, JAMES L. · 2016 to 2021
$24.5MOptimization of Fc effector activity of anti-HIV antibodies to target HIV reservoirR01AI129795 · NIAID · ROCKEFELLER UNIVERSITY · PI NUSSENZWEIG, MICHEL C, RAVETCH, JEFFREY VICTOR · 2017 to 2021
$4.2M3BNC117 and 10-1074 to suppress HIV-1 replication and reduce the reservoirU01AI129825 · NIAID · ROCKEFELLER UNIVERSITY · PI CASKEY, MARINA · 2017 to 2021
$4.0MBill & Melinda Gates Foundation INV-002707NCATS NIH HHS UL1 TR001866NIAID NIH HHS P30 AI124414NIAID NIH HHS R01 AI129795NIAID NIH HHS U01 AI129825NIAID NIH HHS UM1 AI100663NIAID NIH HHS UM1 AI126611NIAID NIH HHS UM1 AI126620NIAID NIH HHS UM1 AI164565
Abstract
Antiretroviral therapy controls, but does not cure, HIV-1 infection due to a reservoir of rare CD4
Indexed as
HIV-1HIV InfectionsHIV SeropositivityCD4-Positive T-LymphocytesClone CellsDNA-Binding ProteinsGene ExpressionHumansNuclear ProteinsProvirusesVirus LatencyDNA-Binding ProteinsLYAR protein, humanNuclear ProteinsCP: Immunology
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.